open access

Vol 10, Supp. F (2014)
suplement
Published online: 2014-12-12
Get Citation

Fulvestrant in the paliative treatment of hormone-sensitive breast cancer

Agnieszka Kolasińska-Ćwikła

open access

Vol 10, Supp. F (2014)
suplement
Published online: 2014-12-12

Abstract

There is strong evidence that endocrine therapy is the preferred option for hormone receptor positive disease according to ABC1 and St. Gallen recommendation. Treatment choice should take into account at least these factors: biology of tumor, sites of metastases, symptoms, performance status; co-morbidities (including organ dysfunctions); and patient preference. The preferred hormone palliative therapy is based on menopausal status. A description of the patient with metastatic breast cancer who during the using of fulvestrant has been reached the long-lasting remission of metastatic lesions.

Abstract

There is strong evidence that endocrine therapy is the preferred option for hormone receptor positive disease according to ABC1 and St. Gallen recommendation. Treatment choice should take into account at least these factors: biology of tumor, sites of metastases, symptoms, performance status; co-morbidities (including organ dysfunctions); and patient preference. The preferred hormone palliative therapy is based on menopausal status. A description of the patient with metastatic breast cancer who during the using of fulvestrant has been reached the long-lasting remission of metastatic lesions.

Get Citation

Keywords

breast cancer, hormonotherapy, fulvestrant

About this article
Title

Fulvestrant in the paliative treatment of hormone-sensitive breast cancer

Journal

Oncology in Clinical Practice

Issue

Vol 10, Supp. F (2014)

Pages

5-7

Published online

2014-12-12

Keywords

breast cancer
hormonotherapy
fulvestrant

Authors

Agnieszka Kolasińska-Ćwikła

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl